Based on these findings, pharmacological agents that can modulate the AMPK/mTOR/IRF5 signaling pathway may inhibit microglial activation, thereby offering significant therapeutic potential for alleviating neuroinflammation and neuronal cell senescence in patients with neurodegenerative diseases, such as AD. The gene discussed is PRKAA1; the disease is Alzheimer disease.